GlobalData on MSN10h
US CDC AdCom recommends lowering the age for pneumococcal vaccinesThe committee voted to lower the recommended age for MSD’s Capvaxive and Pfizer’s Prevnar 20 to 50 years down from 65.
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
In a 15-0 vote, ACIP recommended that MenB-4C be administered as a two-dose series at 0 and 6 months when given to healthy ...
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
The CDC recommends expanding pneumococcal vaccine eligibility to adults aged 50 and above, impacting disease prevention with Pfizer and Merck's vaccines.
An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...
NEW YORK (AP) — U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can ...
Many people don’t know they’re eligible. | Moderna has identified a fundamental barrier to vaccination: many people don’t ...
GlobalData on MSN11h
Alpha-9 becomes latest radiopharma to secure funds with $175m Series CThe company will use the funds to advance its pipeline of cancer-targeting preclinical candidates to the “clinic-ready” stage ...
See your plan by selecting location, age, and other applicable factors Sign up to be alerted when there are vaccination updates in your state: The Plan Your Vaccine page will be updated as new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback